Federated Hermes Inc. raised its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) by 4.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,736 shares of the company’s stock after buying an additional 771 shares during the period. Federated Hermes Inc.’s holdings in Medpace were worth $8,128,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Rise Advisors LLC purchased a new position in shares of Medpace during the first quarter worth $27,000. Mather Group LLC. purchased a new position in Medpace in the first quarter valued at $28,000. Fidelis Capital Partners LLC purchased a new position in Medpace in the first quarter valued at $31,000. J.Safra Asset Management Corp boosted its holdings in Medpace by 87.0% in the first quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock valued at $41,000 after purchasing an additional 47 shares during the period. Finally, DT Investment Partners LLC purchased a new position in Medpace in the second quarter valued at $41,000. 77.98% of the stock is currently owned by hedge funds and other institutional investors.
Medpace Stock Performance
MEDP opened at $354.65 on Wednesday. The business’s 50-day simple moving average is $382.17 and its 200-day simple moving average is $392.66. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The stock has a market capitalization of $10.99 billion, a P/E ratio of 36.15, a price-to-earnings-growth ratio of 1.74 and a beta of 1.36.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on MEDP shares. TD Cowen decreased their target price on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Deutsche Bank Aktiengesellschaft decreased their target price on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a report on Wednesday, July 24th. William Blair reiterated an “outperform” rating on shares of Medpace in a report on Wednesday, September 11th. Truist Financial began coverage on Medpace in a research note on Thursday, August 1st. They issued a “hold” rating and a $415.00 price target on the stock. Finally, Mizuho began coverage on Medpace in a research note on Tuesday, May 28th. They issued a “buy” rating and a $435.00 price target on the stock. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $423.00.
Read Our Latest Research Report on MEDP
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Recommended Stories
- Five stocks we like better than Medpace
- Golden Cross Stocks: Pattern, Examples and Charts
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- How to Calculate Return on Investment (ROI)
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- 3 Warren Buffett Stocks to Buy Now
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.